See also
ˇ Show More
The income statement presents information on the financial results of a company's business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
You have visited 10 password protected pages for free. Others contain data covered by
.
Sign Up Now to get full access to whole website and cut out all advertisements.
AstraZeneca PLC, Consolidated Income Statement
USD $ in millions

| 12 months ended | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
|---|---|---|---|---|---|---|
![]() |
Revenue | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Cost of sales | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Gross profit | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Distribution costs | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Research and development | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Selling, general and administrative costs | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Profit on disposal of subsidiary | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Royalties | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Net gain on disposal of property, plant and equipment | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Gains on disposal of product rights | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Net gain (loss) on disposal of other intangible assets | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Gains on divestments of non-core products | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Impairment of intangible assets relating to future licensing and contractual income | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Other income | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Other expense | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Other operating income and expense | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Operating profit | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Returns on fixed deposits and equity securities | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Returns on short-term deposits | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Expected return on post-employment defined benefit plan assets | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Fair value gains on debt, interest rate swaps and investments | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Net exchange gains | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Finance income | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Interest on debt and commercial paper | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Interest on overdrafts and other financing costs | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Interest on post-employment defined benefit plan liabilities | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Fair value charges on debt, interest rate swaps and investments | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Net exchange losses | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Finance expense | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Profit before tax | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Taxation | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Profit for the period | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Profit attributable to non-controlling interests | ![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Profit attributable to owners of the Parent | ![]() |
![]() |
![]() |
![]() |
![]() |
| Item | Description | The company |
|---|---|---|
| Revenue | Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. | AstraZeneca PLC's revenue increased from 2009 to 2010 and from 2010 to 2011. |
| Operating profit | The net result for the period of deducting operating expenses from operating revenues. | AstraZeneca PLC's operating profit declined from 2009 to 2010 but then increased from 2010 to 2011 exceeding 2009 level. |
| Profit before tax | Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. | AstraZeneca PLC's profit before tax increased from 2009 to 2010 and from 2010 to 2011. |
| Profit for the period | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. | AstraZeneca PLC's profit for the period increased from 2009 to 2010 and from 2010 to 2011. |
| Profit attributable to owners of the Parent | The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. | AstraZeneca PLC's profit attributable to owners of the Parent increased from 2009 to 2010 and from 2010 to 2011. |
Stock Analysis on Net (www.stock-analysis-on.net)
Copyright © 2012 EBIT Financial Analyses Center